Revvity Debt to Equity Ratio 2010-2025 | RVTY
Current and historical debt to equity ratio values for Revvity (RVTY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Revvity debt/equity for the three months ending March 31, 2025 was 0.41.
| Revvity Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $4.72B | $7.64B | 0.62 |
| 2024-12-31 | $4.73B | $7.67B | 0.62 |
| 2024-09-30 | $4.85B | $7.92B | 0.61 |
| 2024-06-30 | $5.56B | $7.87B | 0.71 |
| 2024-03-31 | $5.59B | $7.85B | 0.71 |
| 2023-12-31 | $5.69B | $7.87B | 0.72 |
| 2023-09-30 | $5.73B | $7.69B | 0.74 |
| 2023-06-30 | $6.35B | $7.87B | 0.81 |
| 2023-03-31 | $6.60B | $8.03B | 0.82 |
| 2022-12-31 | $6.75B | $7.38B | 0.91 |
| 2022-09-30 | $6.76B | $7.07B | 0.96 |
| 2022-06-30 | $7.02B | $7.17B | 0.98 |
| 2022-03-31 | $7.66B | $7.19B | 1.07 |
| 2021-12-31 | $7.86B | $7.14B | 1.10 |
| 2021-09-30 | $7.94B | $6.96B | 1.14 |
| 2021-06-30 | $4.50B | $4.24B | 1.06 |
| 2021-03-31 | $4.76B | $4.00B | 1.19 |
| 2020-12-31 | $4.23B | $3.74B | 1.13 |
| 2020-09-30 | $3.63B | $3.23B | 1.12 |
| 2020-06-30 | $3.67B | $2.97B | 1.24 |
| 2020-03-31 | $3.63B | $2.76B | 1.31 |
| 2019-12-31 | $3.73B | $2.81B | 1.32 |
| 2019-09-30 | $3.78B | $2.71B | 1.40 |
| 2019-06-30 | $3.69B | $2.71B | 1.36 |
| 2019-03-31 | $3.45B | $2.64B | 1.31 |
| 2018-12-31 | $3.39B | $2.59B | 1.31 |
| 2018-09-30 | $3.29B | $2.57B | 1.28 |
| 2018-06-30 | $3.44B | $2.52B | 1.37 |
| 2018-03-31 | $3.57B | $2.56B | 1.40 |
| 2017-12-31 | $3.59B | $2.50B | 1.43 |
| 2017-09-30 | $2.20B | $2.54B | 0.87 |
| 2017-06-30 | $2.17B | $2.44B | 0.89 |
| 2017-03-31 | $2.13B | $2.21B | 0.97 |
| 2016-12-31 | $2.12B | $2.15B | 0.99 |
| 2016-09-30 | $2.17B | $2.14B | 1.02 |
| 2016-06-30 | $2.11B | $2.09B | 1.01 |
| 2016-03-31 | $2.16B | $2.05B | 1.06 |
| 2015-12-31 | $2.06B | $2.11B | 0.97 |
| 2015-09-30 | $1.98B | $2.05B | 0.96 |
| 2015-06-30 | $1.96B | $2.12B | 0.93 |
| 2015-03-31 | $1.97B | $2.06B | 0.96 |
| 2014-12-31 | $2.09B | $2.04B | 1.02 |
| 2014-09-30 | $1.82B | $2.06B | 0.88 |
| 2014-06-30 | $1.88B | $2.06B | 0.92 |
| 2014-03-31 | $1.94B | $2.03B | 0.96 |
| 2013-12-31 | $1.95B | $1.99B | 0.98 |
| 2013-09-30 | $1.93B | $1.92B | 1.01 |
| 2013-06-30 | $1.95B | $1.86B | 1.05 |
| 2013-03-31 | $1.97B | $1.83B | 1.08 |
| 2012-12-31 | $1.96B | $1.94B | 1.01 |
| 2012-09-30 | $1.95B | $1.94B | 1.00 |
| 2012-06-30 | $1.92B | $1.89B | 1.02 |
| 2012-03-31 | $1.98B | $1.88B | 1.05 |
| 2011-12-31 | $2.01B | $1.84B | 1.09 |
| 2011-09-30 | $1.46B | $1.95B | 0.75 |
| 2011-06-30 | $1.64B | $1.96B | 0.84 |
| 2011-03-31 | $1.40B | $1.91B | 0.73 |
| 2010-12-31 | $1.28B | $1.93B | 0.67 |
| 2010-09-30 | $1.54B | $1.71B | 0.90 |
| 2010-06-30 | $1.50B | $1.64B | 0.91 |
| 2010-03-31 | $1.40B | $1.63B | 0.86 |
| 2009-12-31 | $1.43B | $1.63B | 0.88 |
| 2009-09-30 | $1.46B | $1.60B | 0.91 |
| 2009-06-30 | $1.37B | $1.57B | 0.87 |
| 2009-03-31 | $1.35B | $1.51B | 0.89 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.588B | $2.755B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $133.694B | 25.08 |
| Elevance Health (ELV) | United States | $90.401B | 11.66 |
| CVS Health (CVS) | United States | $78.570B | 9.77 |
| Cencora (COR) | United States | $56.472B | 19.65 |
| DiDi Global (DIDIY) | China | $22.450B | 34.07 |
| Natera (NTRA) | United States | $20.631B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.588B | 13.33 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.514B | 0.00 |
| CochLear (CHEOY) | Australia | $11.382B | 0.00 |
| ICON (ICLR) | Ireland | $10.225B | 9.51 |
| Viatris (VTRS) | United States | $9.953B | 3.42 |
| Doximity (DOCS) | United States | $9.475B | 44.13 |
| Avantor (AVTR) | United States | $8.552B | 12.43 |
| HealthEquity (HQY) | United States | $8.545B | 42.04 |
| Medpace Holdings (MEDP) | United States | $8.501B | 22.58 |
| Sonic Healthcare (SKHHY) | Australia | $8.263B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.630B | 12.99 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.137B | 38.29 |
| Bausch + Lomb (BLCO) | Canada | $3.955B | 23.31 |
| Sotera Health (SHC) | United States | $3.503B | 19.90 |
| Alignment Healthcare (ALHC) | United States | $3.033B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.905B | 37.78 |
| Concentras Parent (CON) | United States | $2.803B | 16.20 |
| Organon (OGN) | United States | $2.191B | 2.33 |
| Ardent Health Partners (ARDT) | United States | $2.137B | 9.11 |
| GeneDx Holdings (WGS) | United States | $1.934B | 74.48 |
| Premier (PINC) | United States | $1.899B | 14.41 |
| Progyny (PGNY) | United States | $1.816B | 39.98 |
| PACS (PACS) | United States | $1.506B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.354B | 27.07 |
| Pediatrix Medical (MD) | United States | $1.303B | 9.91 |
| Teladoc Health (TDOC) | United States | $1.223B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.037B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| Agilon Health (AGL) | United States | $0.973B | 0.00 |
| CareDx (CDNA) | United States | $0.949B | 14.83 |
| Nutex Health (NUTX) | United States | $0.941B | 14.21 |
| AMN Healthcare Services Inc (AMN) | United States | $0.846B | 7.92 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.722B | 4.86 |
| InnovAge Holding (INNV) | United States | $0.554B | 0.00 |
| Enhabit (EHAB) | United States | $0.528B | 43.46 |
| Auna S.A (AUNA) | Luxembourg | $0.506B | 11.40 |
| LifeMD (LFMD) | United States | $0.489B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.467B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.403B | 0.00 |
| SBC Medicals (SBC) | United States | $0.360B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.204B | 0.00 |
| Oncology Institute (TOI) | United States | $0.202B | 0.00 |
| Beauty Health (SKIN) | United States | $0.195B | 0.00 |
| KindlyMD (KDLY) | United States | $0.137B | 0.00 |
| DocGo (DCGO) | United States | $0.131B | 21.33 |
| So-Young (SY) | China | $0.089B | 0.00 |
| OncoCyte (OCX) | United States | $0.088B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.072B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| Biodesix (BDSX) | United States | $0.058B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.036B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |